Published in Blood Weekly, December 27th, 2007
"We are very pleased that ASH accepted these 12 studies for presentation," said Craig Tendler, M.D., Vice President, Medical Affairs, Oncology/Nephrology, Ortho Biotech Products, L.P. "These presentations are further evidence of Ortho Biotech's ongoing commitment to developing oncology therapeutics and to helping patients with cancer."
Keywords: Biotechnology, Biotechnology Business, Biotechnology...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.